

### Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Savella under the patient's prescription drug benefit.

# **Description:**

### FDA-approved Indications

Savella is indicated for the management of fibromyalgia.

Savella is not approved for use in pediatric patients.

### **Drug List:**

Savella

### **Policy/Guideline:**

### **Coverage Criteria**

### **Fibromyalgia**

Authorization may be granted when the requested drug is being prescribed for the management of fibromyalgia when ALL of the following criteria are met:


- The patient is 18 years of age or older
- The patient meets ONE of the following:
  - The patient has experienced an inadequate treatment response to duloxetine OR pregabalin
  - The patient has experienced an intolerance to duloxetine OR pregabalin
  - The patient has a contraindication that would prohibit a trial of ALL of the following: duloxetine, pregabalin

### **Continuation of Therapy**

### **Fibromyalgia**

Authorization may be granted when the requested drug is being prescribed for the management of fibromyalgia when ALL of the following criteria are met:

- The patient is 18 years of age or older
- The patient has achieved or maintained a positive clinical response to the requested drug (e.g., improvement in pain)



# **Approval Duration and Quantity Restrictions:**

### Initial and Renewal Approval:

- Initial approval: 6 months
- Renewals: 12 months

Quantity Level Limits: Reference formulary for specific quantity limits.

#### **References:**

- 1. Savella [package insert]. North Chicago, IL: AbbVie Inc.; December 2023.
- 2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed April 18, 2024.
- 3. Micromedex<sup>®</sup> (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 04/18/2024).
- 4. Winslow BT; Vandal C; Dang, L. Fibromyalgia: Diagnosis and Management. American Family Physician. February 2023; 107(2): 137-144